What does FetTech do?

FetTech is a biotechnology company founded in 2013 by Danielle and Clay Fette, focusing on regenerative medicine through its proprietary Multi-Tissue Platform (MTP®) technology. This innovative approach utilizes multiple extracellular matrix (ECM) tissues to deliver biomolecules that support natural tissue repair and healing. Headquartered in the U.S., FetTech employs 11-50 people and is dedicated to developing FDA-cleared medical devices for various applications, including wound care, trauma, burns, surgery, aesthetics, and emerging fields like nerve repair and cardiac regeneration. The company's core products include Stemsys® (XCelliStem® Wound Powder), an advanced wound healing solution, and ReyaGel, the first FDA-cleared liquid ECM for skin recovery and tissue regeneration. FetTech is committed to patient-first innovation, emphasizing integrity and natural healing solutions. Their products are trusted in U.S. hospitals and surgical settings, with ongoing advancements in antiviral therapies and regenerative medicine. The leadership team, with extensive experience in nursing and medical devices, aims to redefine healthcare possibilities through natural healing.